Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Anticancer Research|July 3, 2017
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung CancerGiuseppe L Banna, Hector Josè Soto Parra, Marine Castaing, et al.
Frontiers in Oncology|September 25, 2020
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer PatientsChristian Britschgi, Alfredo Addeo, Markus Rechsteiner, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 22, 2020
Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancerGiuseppe L Banna, Valeria Urzia, Chiara Benanti, et al.
Translational Lung Cancer Research|March 4, 2022
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective studyHuiping Qiang, Yuqiong Lei, Yinchen Shen, et al.
International Immunopharmacology|July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective studyGiuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.
European Radiology|September 8, 2025
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methodsAlmudena Fuster-Matanzo, Alfonso Picó-Peris, Fuensanta Bellvís-Bataller, et al.
Current Oncology Reports|April 23, 2024
Antibody Drug Conjugates in Urological Cancers: A Review of the Current LandscapeAruni Ghose, Patricia Lapitan, Vedika Apte, et al.
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
Pageof 5